C4 Therapeutics, Inc.: RA CAPITAL MANAGEMENT, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
RA Capital Management, L.P. amended its Schedule 13G stake filing for C4 Therapeutics, Inc., disclosing the change to the SEC under accession number 0001346824-26-000277. The filing updates the investment firm's previously reported beneficial ownership position in the clinical-stage biotech, which develops targeted protein degradation therapies. The amendment signals a change in RA Capital's holdings, though the filing itself does not specify the direction or size of the adjustment. Investors will watch for further 13G or 13D filings to gauge whether the firm is accumulating or trimming its position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
RA Capital Management, L.P., C4 Therapeutics, Inc.